Clinical Trials Browser

Glioblastoma × relatlimab × 90 days × Clear all

NCT06325683 2026-06-03

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

Phase 2 Suspended

Glioblastoma